Ixekizumab Associated New-Onset Inflammatory Bowel Disease.
Journal
ACG case reports journal
ISSN: 2326-3253
Titre abrégé: ACG Case Rep J
Pays: United States
ID NLM: 101638398
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
07
08
2019
accepted:
18
12
2019
entrez:
23
5
2020
pubmed:
23
5
2020
medline:
23
5
2020
Statut:
epublish
Résumé
Ixekizumab is a monoclonal antibody targeting interleukin-17 approved for the treatment of psoriasis. In a recent post hoc meta-analysis of Phase-I to Phase-III clinical trials of anti-interleukin-17 agents for the treatment of plaque psoriasis, there was a rare association (<1%) with induction or exacerbation of inflammatory bowel disease. We report a case of new-onset ileal Crohn's disease in a 48-year-old woman on ixekizumab for psoriasis.
Identifiants
pubmed: 32440523
doi: 10.14309/crj.0000000000000316
pii: ACGCR-19-0600
pmc: PMC7209798
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e00316Informations de copyright
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Curr Gastroenterol Rep. 2010 Aug;12(4):249-58
pubmed: 20532706
Int J Mol Sci. 2015 Sep 01;16(9):20841-58
pubmed: 26340622
J Crohns Colitis. 2018 Aug 29;12(9):1131-1133
pubmed: 29746636
Pharmacol Rep. 2011;63(1):30-44
pubmed: 21441609
Aliment Pharmacol Ther. 2019 Aug;50(4):373-385
pubmed: 31309607
N Engl J Med. 2016 Jul 28;375(4):345-56
pubmed: 27299809
Gut. 2012 Dec;61(12):1693-700
pubmed: 22595313
N Engl J Med. 2014 Jul 24;371(4):326-38
pubmed: 25007392
Am J Gastroenterol. 2019 Jan;114(1):179-180
pubmed: 30429591
Am J Gastroenterol. 2016 Nov;111(11):1599-1607
pubmed: 27481309
N Engl J Med. 2012 Mar 29;366(13):1190-9
pubmed: 22455413
Gut. 2003 Jan;52(1):65-70
pubmed: 12477762
Case Rep Gastroenterol. 2018 Oct 17;12(3):617-621
pubmed: 30483039
ACG Case Rep J. 2018 Aug 1;5:e56
pubmed: 30105273